)
)
)
Tessera Therapeutics is pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Our mission is to cure disease by writing in the code of life.
Year Founded
2018
Expected time of next catalyst update
2026
City
Somerville
Country
United States
Company CEO or top company official
Michael Severino
Development Phase of Primary Product
Phase I
Lead Product in Development
In vivo gene editing of alpha-1 antitrypsin deficiency (AATD).
Therapeutic Area
Multiple Therapeutics
Website
https://www.tesseratherapeutics.com/
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
